grant
Circulating cell free tumor DNA (ctDNA) in patients with immune checkpoint inhibitor associated inflammatory arthritis (ICI-IA): developing a biomarker to assess immunosuppressive drug safety
Organization HOSPITAL FOR SPECIAL SURGERYLocation New York, UNITED STATESPosted 16 Sept 2025Deadline 31 Aug 2028
NIHUS FederalResearch GrantFY2025(TNF)-α1, 2-DehydrocortisoneAddressAdvanced CancerAdvanced Malignant NeoplasmAdverse ExperienceAdverse eventArthroplastyAssayAutoimmuneB-Cell Differentiation Factor GeneB-Cell Stimulatory Factor 2 GeneBSF-2 GeneBSF2 GeneBeta-2 Gene InterferonBioassayBiological AssayBiological MarkersBlocking AntibodiesBlood PlasmaCD126 AntigensCD126 ReceptorCachectinCachectin ReceptorsCancer PatientCancersCell BodyCellsCheckpoint inhibitorChronicClinicClinicalClinical Treatment MoabCoupledCouplesDMARDDMARDsDNADataDehydrocortisoneDelta(1)-CortisoneDeltacortisoneDeltadehydrocortisoneDeoxyribonucleic AcidDiseaseDisease-Modifying Antirheumatic DrugsDisease-Modifying Second-Line DrugsDisorderDrug TherapyDrugsEligibilityEligibility DeterminationEnrollmentFutureGenomicsGlucocorticoidsHSF GeneHepatocyte Stimulatory Factor GeneHybridoma Growth Factor GeneIFNB2 GeneIL-6 GeneIL-6 ReceptorsIL6IL6 ReceptorsIL6 geneImageImmune checkpoint inhibitorImmune mediated therapyImmune systemImmunologically Directed TherapyImmunosuppressantsImmunosuppressionImmunosuppression EffectImmunosuppressive AgentsImmunosuppressive EffectImmunosuppressive drugImmunosuppressive treatmentImmunotherapyIndividualInflammatory ArthritisInstitutionInterleukin 6 (Interferon, Beta 2) GeneInterleukin 6 ReceptorInterleukin-6 GeneInterventionIntervention StudiesJoint Prosthesis ImplantationJointsKineticsMacrophage-Derived TNFMalignant CellMalignant MelanomaMalignant NeoplasmsMalignant TumorMeasurementMeasuresMedicationMelanomaMelanoma patientMetacortandracinMethotrexateMethotrexate MethylaminopterinMethotrexatumMetotrexatoMonoclonal AntibodiesMonocyte-Derived TNFNSCLCNSCLC - Non-Small Cell Lung CancerNatureNon-Small Cell Lung CancerNon-Small-Cell Lung CarcinomaObservation researchObservation studyObservational StudyObservational researchOperative ProceduresOperative Surgical ProceduresPatientsPharmaceutical PreparationsPharmacological TreatmentPharmacotherapyPhenotypePlasmaPlasma SerumPrednisonePrednisonumProgression-Free SurvivalsProtocol ScreeningRadiographyRecurrent Malignant NeoplasmRecurrent Malignant TumorRegistriesReplacement ArthroplastyReticuloendothelial System, Serum, PlasmaRheumatologyRoentgenographySamplingSomatic MutationSpecial HospitalsSteroid CompoundSteroidsSurgicalSurgical InterventionsSurgical ProcedureT-Cell ActivationTNFTNF ATNF AlphaTNF Receptor Family ProteinTNF Receptor SuperfamilyTNF ReceptorsTNF geneTNF-αTNFATNFRTNFαTestingTimeTumor BurdenTumor ImmunityTumor LoadTumor Necrosis FactorTumor Necrosis Factor ReceptorTumor Necrosis Factor Receptor FamilyTumor Necrosis Factor Receptor SuperfamilyTumor Necrosis Factor-alphaTumor TissueVisitactivate T cellsanti-canceranti-tumor immunityantitumor immunityarthritis registrybio-markersbiologic markerbiomarkercancer biomarkerscancer cellcancer immunitycancer markerscancer progressioncancer recurrencecancer survivalcombatdeep learningdeep learning methoddeep learning strategydelta-Cortisonedetection sensitivitydrug interventiondrug safetydrug treatmentdrug/agentenrollentire genomeevidence basefull genomegenome sequencingimagingimmune check point inhibitorimmune suppressionimmune suppressive activityimmune suppressive agentimmune suppressive functionimmune suppressorimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmune-mediated adverse eventsimmune-related adverse effectimmune-related adverse eventsimmune-related adverse reactionimmuno therapyimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunosuppressive substanceimmunosuppressorimprovedinhibitorintervention researchinterventional researchinterventional studyinterventions researchjoint arthroplastyjoint replacementmAbsmalignancymedication safetymonoclonal Absneoplasm progressionneoplasm/cancerneoplastic progressionnovelparticipant enrollmentpatient enrollmentpatients suffering from melanomapatients with melanomapharmaceutical interventionpharmaceutical safetypharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticsprognosticprospectiveradiological imagingresponserheumatologistside effectsomatic variantstandard of caresuccesssurgerytargeted sequencingtumortumor DNAtumor cell DNAtumor progressiontumor-specific DNAwhole genome
Description preview
PROJECT SUMMARY
Immune checkpoint inhibitors (ICI) are monoclonal antibodies that block regulators of T cell activation,
activating anti-cancer immunity and greatly improving overall survival in patients with advanced cancer.
However, ICI commonly cause immune related adverse events (irAE), including inflammatory arthritis (ICI-IA).
It is…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click